Analyst Ratings For FENC – Fennec Pharmaceuticals (NASDAQ:FENC)
Today, HC Wainwright reiterated its Buy rating on FENC – Fennec Pharmaceuticals (NASDAQ:FENC) with a price target of $18.00.
Some recent analyst ratings include
- 4/2/2018-HC Wainwright Reiterated Rating of Buy.
- 3/12/2018-Wedbush initiated coverage with a Outperform rating.
- 11/29/2017-Laidlaw initiated coverage with a Buy rating.
Recent Insider Trading Activity For FENC – Fennec Pharmaceuticals (NASDAQ:FENC)
FENC – Fennec Pharmaceuticals (NASDAQ:FENC) has insider ownership of 10.70% and institutional ownership of 44.94%.
- On 3/28/2018 Manchester Management Pr, Llc, Major Shareholder, sold 914,745 with an average share price of $10.61 per share and the total transaction amounting to $9,705,444.45.
- On 12/12/2017 Spa Essetifin, Major Shareholder, bought 294,115 with an average share price of $8.50 per share and the total transaction amounting to $2,499,977.50.
Recent Trading Activity for FENC – Fennec Pharmaceuticals (NASDAQ:FENC)
Shares of FENC – Fennec Pharmaceuticals closed the previous trading session at with 12.25 shares trading hands.